We are live on
!
Find out more
CPI
Canaan Partners IX Portfolio holdings
AUM
$87.5M
This Fund
S&P 500
This Quarter
Est. Return
+61.78%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$102M
AUM Growth
–
Cap. Flow
+$77.3M
Cap. Flow
% of AUM
75.82%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
1
New
1
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CytomX Therapeutics
CTMX
|
+$77.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CytomX Therapeutics
CTMX
$788M
| $102M | 100% |
+4,884,755
| New | +$77.3M |
|
Similar funds
HH
SLM
JAM
TIMH
TCM
CCFP
PC
BAM
Canaan Partners IX's Q4 2015 Portfolio in Review
Q4 2015 is the first quarter with a 13F filing on record for Canaan Partners IX, which disclosed 1 position worth $102M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is CytomX Therapeutics: 4,884,755 shares worth $102M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Canaan Partners IX's largest Q4 2015 buy was CytomX Therapeutics: 4,884,755 shares worth $102M.
- Canaan Partners IX's ten largest holdings make up 100% of its $102M portfolio in Q4 2015.
- Canaan Partners IX disclosed 1 position in Q4 2015, its first 13F filing on record.
Based on Canaan Partners IX's 13F filing for Q4 2015, filed 11 Feb 2016.